Clinical Trials
25 trialsERIS
Region Skane
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
Shanghai Chest Hospital
M13DAP
The Netherlands Cancer Institute
Phase 2 Study of Dacomitinib in NSCLC
National Cancer Centre, Singapore
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
National Cancer Centre, Singapore
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Memorial Sloan Kettering Cancer Center
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
DRUP
The Netherlands Cancer Institute
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
Shanghai Chest Hospital
CAPLAND
Fondazione Ricerca Traslazionale
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Grupo Español de Investigación en Neurooncología
HER-Uro01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Central Nervous System(CNS) Efficacy of Dacomitinib
Samsung Medical Center
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Guangdong Association of Clinical Trials
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Central European Cooperative Oncology Group
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Massachusetts General Hospital
A Phase II Study of Dacomitinib in Progressive Brain Metastases
University of California, San Diego
Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
University Health Network, Toronto
PF299804-AGC
Seoul National University Hospital
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
University Health Network, Toronto
A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma
University Health Network, Toronto
PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Yonsei University